Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Delcath Systems from “hold” to “buy,” while HC Wainwright and BTIG also maintained buy ratings and raised their price targets. The stock has a consensus “Moderate Buy” rating and average price target of $23.17.
• Quarterly results exceeded expectations: Delcath reported $0.07 in earnings per share versus estimates for a $0.09 loss, while revenue reached $29.13 million against a $26.25 million consensus estimate.
• The company issued fiscal 2026 revenue guidance of $104 million to $108 million, slightly above analyst expectations, although shares remain highly valued and recently traded near their 52-week high.

Delcath Systems (NASDAQ:DCTH - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

Several other equities research analysts also recently commented on DCTH. HC Wainwright reissued a "buy" rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday. Weiss Ratings raised shares of Delcath Systems from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday, May 11th. Zacks Research raised shares of Delcath Systems from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 7th. Finally, BTIG Research boosted their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Delcath Systems currently has a consensus rating of "Moderate Buy" and an average price target of $23.17.

Delcath Systems Trading Down 2.3%

DCTH stock opened at $15.11 on Friday. The stock has a 50-day moving average price of $12.35 and a two-hundred day moving average price of $10.87. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $16.38. The stock has a market cap of $521.60 million, a PE ratio of 1,512.51 and a beta of 0.52.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.47% and a net margin of 0.56%.The firm had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. On average, analysts forecast that Delcath Systems will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DCTH. Rosalind Advisors Inc. lifted its holdings in shares of Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company's stock worth $44,885,000 after acquiring an additional 400,000 shares during the period. Vanguard Group Inc. boosted its position in shares of Delcath Systems by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company's stock worth $17,817,000 after acquiring an additional 46,693 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Delcath Systems in the third quarter valued at approximately $7,164,000. Goldman Sachs Group Inc. increased its stake in Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company's stock valued at $5,936,000 after acquiring an additional 315,583 shares during the last quarter. Finally, ExodusPoint Capital Management LP raised its position in Delcath Systems by 30.9% during the fourth quarter. ExodusPoint Capital Management LP now owns 496,705 shares of the company's stock valued at $5,017,000 after purchasing an additional 117,122 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source